168 related articles for article (PubMed ID: 32184064)
1. Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma.
Patel A; Borczuk AC; Siddiqui MT
J Am Soc Cytopathol; 2020; 9(3):146-151. PubMed ID: 32184064
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Utility of Claudin4 and Comparison with BerEp4 as a Marker for Metastatic Adenocarcinoma in Serous Effusions.
Mangla G; Bakshi P; Agarwal P; Verma K
Acta Cytol; 2023; 67(5):564-572. PubMed ID: 37331346
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Value of Claudin-4 and EZH2 Immunohistochemistry in Effusion Cytology.
Elhosainy A; Hafez MMA; Yassin EH; Adam M; Elnaggar MS; Aboulhagag NA
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2779-2785. PubMed ID: 36037134
[TBL] [Abstract][Full Text] [Related]
4. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
Jo VY; Cibas ES; Pinkus GS
Cancer Cytopathol; 2014 Apr; 122(4):299-306. PubMed ID: 24421209
[TBL] [Abstract][Full Text] [Related]
5. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
[TBL] [Abstract][Full Text] [Related]
6. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Usefulness of Claudin-3 and Claudin-4 for Immunocytochemical Differentiation between Metastatic Adenocarcinoma Cells and Reactive Mesothelial Cells in Effusion Cell Blocks.
Kim NI; Kim GE; Lee JS
Acta Cytol; 2016; 60(3):232-9. PubMed ID: 27387183
[TBL] [Abstract][Full Text] [Related]
8. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
9. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
10. The utility of claudin-4 versus MOC-31 and Ber-EP4 in the diagnosis of metastatic carcinoma in cytology specimens.
Najjar S; Gan Q; Stewart J; Sneige N
Cancer Cytopathol; 2023 Apr; 131(4):245-253. PubMed ID: 36522809
[TBL] [Abstract][Full Text] [Related]
11. Claudin-4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study.
Hruaii V; Thirunavukkarasu B; Prabha V; Mathur S; Iyer VK; Nambirajan A; Jain D
Diagn Cytopathol; 2024 Jan; 52(1):30-41. PubMed ID: 37837242
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
Afify A; Zhou H; Howell L; Paulino AF
Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
[TBL] [Abstract][Full Text] [Related]
13. Claudin-4 immunohistochemistry is a useful pan-carcinoma marker for serous effusion specimens.
Vojtek M; Walsh MD; Papadimos DJ; Shield PW
Cytopathology; 2019 Nov; 30(6):614-619. PubMed ID: 31390089
[TBL] [Abstract][Full Text] [Related]
14. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
15. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
16. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
Delahaye M; van der Ham F; van der Kwast TH
Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
[TBL] [Abstract][Full Text] [Related]
17. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
18. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
19. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
Bernardi L; Bizzarro T; Pironi F; Szymczuk S; Buda R; Fabbri E; Di Claudio G; Rossi G
Cancer Cytopathol; 2021 Apr; 129(4):275-282. PubMed ID: 33045147
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of Metastatic Carcinoma Using Body Cavity Fluid Specimens: A Comparison of Diagnostic Panels.
Sridakhun N; Intarawichian P; Thanee M; Watcharadetwittaya S
Acta Cytol; 2023; 67(3):257-264. PubMed ID: 36513033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
